News | October 10, 2025
AstraZeneca to increase investment in Virginia manufacturing facility to $4.5 billion
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
The FDA is beginning rulemaking to close the “adequate provision” loophole
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Subscribe To Our Newsletter & Stay Updated
